Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
Cytokinetics announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress, focusing largely on its cardiac myosin inhibitor MYQORZO® (aficamten), recently approved in major markets including the US, Europe, and China for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The presentations will highlight cl…